目的 探討生脈膠囊聯(lián)合米力農注射液治療缺血性心肌病的臨床效果。方法 選取2015年7月-2017年7月南陽市中心醫(yī)院收治的缺血性心肌病患者106例，隨機分為對照組（53例）和治療組（53例）。對照組在1~7 d靜脈注射米力農注射液，首次負荷劑量為50 μg/kg，5~10 min緩靜注完，再以0.5 μg/（kg·min）進行維持治療，最大劑量 ≤ 1.13 mg/（kg·d）。治療組在對照組基礎上口服生脈膠囊，0.9 g/次，3次/d。兩組患者均連續(xù)治療2周。評價兩組患者臨床療效，同時比較治療前后兩組患者臨床癥狀積分、血清炎性因子和血漿腦鈉肽（BNP）水平及心功能指標。結果 治療后，對照組和治療組臨床有效率分別為73.58%和92.45%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者各項癥狀積分均顯著減少（P<0.05），且治療組臨床癥狀積分明顯低于對照組（P<0.05）。治療后，兩組血清C反應蛋白（CRP）、腫瘤壞死因子（TNF）-α和血漿BNP水平較治療前均顯著降低P<0.05），且治療后治療組明顯低于對照組（P<0.05）。治療后，兩組左室舒張末期內徑（LVEDD）、左室收縮末期內徑（LVESD）值均顯著降低（P<0.05），左室射血分數(shù)（LVEF）值顯著增加（P<0.05），同時，治療組治療后心功能指標明顯優(yōu)于對照組（P<0.05）。結論 生脈膠囊聯(lián)合米力農注射液治療缺血性心肌病更能迅速緩解患者癥狀體征，減輕機體炎性損傷，提高心功能。

Objective To investigate the clinical effect of Shengmai Capsules combined with Milrinone Injection in treatment of ischemic cardiomyopathy. Methods Patients (106 cases) with ischemic cardiomyopathy in Nanyang City Central Hospital from July 2015 to July 2017 were randomly divided into control (53 cases) and treatment (53 cases) groups. Patients in the control group were iv administered with Milrinone Injection, the first loading dose was 50 μg/kg for 5-10 min, then maintained with 0.5 μg/(kg·min), and the maximum dose was less than 1.13 mg/(kg·d). Patients in the treatment group were po administered with Shengmai Capsules on the basis of the control group, 0.9 g/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacy was evaluated, the clinical symptom scores, the serum inflammatory factors and plasma BNP levels, and the cardiac function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 73.58% and 92.45% respectively, and there were differences between two groups (P<0.05). After treatment, the clinical symptom scores in two groups were significantly decreased (P<0.05), and the scores in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the CRP, TNF-α and BNP levels in two groups were significantly decreased (P<0.05), at the same time, the serum inflammatory factors and plasma BNP levels in the treatment group after treatment were significantly lower than those in the control group (P<0.05). After treatment, the LVEDD and LVESD in two groups were significantly decreased (P<0.05), LVEF was significantly increased (P<0.05), and the cardiac function indexes in the treatment group after treatment were significantly better than those in the control group (P<0.05). Conclusion Shengmai Capsules combined with Milrinone Injection in treatment of ischemic cardiomyopathy can quickly alleviate the disease symptoms and signs, reduce the inflammatory injury, which has a certain clinical application value.